Monoclonal Antibody (Mab)

The CEACAM protein is over-expressed on >95% of pancreatic cancer patients. CEACAM6 is also over-expressed in colon cancers, as well as breast, lung, ovarian cancers and certain childhood leukemias.

Studies using the CEACAM6 Mab have demonstrated high levels of effectiveness and efficacy in mouse models. The Antibody binds to the CEACAM6 oncogene and interferes with its function, promoting apoptosis. CEACAM6 Mab is highly targeted and humanized. Therefore the Mab is projected to have extremely low toxicity, resulting in a very safe and effective treatment for pancreatic cancer.

The antibody was designed as a humanized anti-CEACAM6 single chain variable fragment (scFv) based on the murine Mab 13-1. PEGylation of the glycine-serine linker was used to enhance plasma half-life. The scFv bound CEACAM6 with high affinity, exhibited cytotoxic activity and induced dose-dependent PARP-cleavage in KRas mutated and wild type pancreatic cancer cell lines. Murine PDA xenograft models treated with low doses of humanized scFv-PEG alone elicited tumor growth inhibition, which was enhanced in combination with gemcitabine. Immunohistochemistry of harvested tumors showed significant apoptosis, with inhibition of angiogenesis and proliferation.

CEACAM6 Mab is protected by Patent # 8038996. The patent claims allow for a method of treating various types of cancer using an anti-CEACAM6 monoclonal antibody that induces apoptosis in cancer cells.

TCT-2 NPM1 Small Molecule
NCS348884 (NPM1)

NCS348884 interacts with the oncogene Nucleophosmin-1 (NPM1). Nucleophosmin 1 (NPM1), a multifunctional nucleolar phosphoprotein is dysregulated in human malignancies, leading to anti-apoptosis and inhibition of differentiation. We evaluated the precise three-dimensional structure of NPM 1 based on the highly conserved structure of Xenopus NO38 and its requirement to form dimers and pentamers. Molecular modeling, pharmacophore design, in silico screening and interactive Docking identified NSC348884 as a putative NPM 1 small molecule inhibitor that disrupts a defined hydrophobic pocket required for oligomerization.

Treatment of several different cancer cell types with NSC348884 up-regulated p53 and induced apoptosis in a dose-dependent manner that correlated with apoptotic markers. Further, NSC348884 exquisitely synergizes with doxorubicin on cancer cell viability. The data show that NSC34884 induces apoptosis and synergizes with chemotherapy.

NCS348884 is protected by Patent # 8063089. The patent claims allow for a method for treating cancer by administering an effective amount of the product to treat colon, lung, breast, and prostate cancers, or mantle cell lymphoma or acute leukemia.

About Us

TCT has two patented products that have been successfully tested on mice for several cancers


Learn more about TCT leadership.


TCT has two patented products that have been successfully tested on mice for several cancers


Learn more about TCT Research.

Want to learn more?

Discover how TCTA is developing innovative therapies for treating cancer